(Q36088058)

12 August 2017

1 reference

title

Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases (English)

1 reference

12 August 2017

1 reference

2

D Isenberg

1 reference

12 August 2017

S A Chambers

1

1 reference

12 August 2017

language of work or name

1 reference

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

14

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

210-214

1 reference

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

The mechanisms of action of rituximab in the elimination of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

B cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Pathogenesis of rheumatoid arthritis. Role of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Evaluation of free and peptide bound collagen crosslink excretion in different skeletal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

The role of B cells in lpr/lpr-induced autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon schuss views

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Stevens-Johnson syndrome after treatment with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

Rituximab therapy for HIV-associated Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2138OA

10.1191/0961203305LU2138OA

21 January 2018

Identifiers

DOI

1 reference

release_cqe4rt6u6bgzpfp7dxhwxqqsvi

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cqe4rt6u6bgzpfp7dxhwxqqsvi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference